Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 9NIH 8INDUSTRY 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 179Leukemia 162Lymphoma 116Lung Neoplasms 107Carcinoma, Non-Small-Cell Lung 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Central Nervous System Neoplasms 84Sarcoma 82Prostatic Neoplasms 81Ovarian Neoplasms 76Colorectal Neoplasms 71Head and Neck Neoplasms 70Leukemia, Myeloid, Acute 60Squamous Cell Carcinoma of Head and Neck 54Rectal Neoplasms 54Neuroblastoma 52Colonic Neoplasms 52Multiple Myeloma 51Uterine Cervical Neoplasms 47Brain Neoplasms 46Lymphoma, Large B-Cell, Diffuse 45Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Ovarian Epithelial 41Burkitt Lymphoma 41Astrocytoma 40Glioblastoma 39Fallopian Tube Neoplasms 39Neoplasm Metastasis 38Congenital Abnormalities 37Lymphoma, Follicular 36

Interventions

motesanib diphosphate 1batifiban 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NETWORK × Carcinoma, Islet Cell × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡